Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

Key facts

Study ID

NCT02826603

Run by

Novartis Pharmaceuticals

People needed

1114

Starts

2016-06-22

Expected to finish

2018-07-09

Last updated by the study team

2019-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must give a written, signed and dated informed consent
• Chronic plaque-type psoriasis present for at least 6 months before randomization
• Moderate to severe plaque psoriasis as defined at randomization by:
• PASI score of ≥12 and
• Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and
• IGA mod 2011 ≥3 (based on a scale of 0-4)
• Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
• Topical treatment (including topical corticosteroids) and/or
• Phototherapy and/or
• Previous systemic therapy

You may not qualify if…

• Forms of psoriasis other than plaque psoriasis
• Drug-induced psoriasis
• Ongoing use of prohibited treatments
• Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23
• Use of any other investigational drugs within 5 half-lives of the investigational treatment before study drug initiation
• Pregnant or nursing (lactating) women
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Birmingham, Alabama, United States
• Novartis Investigative Site — Birmingham, Alabama, United States
• Novartis Investigative Site — Mobile, Alabama, United States
• Novartis Investigative Site — Glendale, Arizona, United States
• Novartis Investigative Site — Phoenix, Arizona, United States
• Novartis Investigative Site — Phoenix, Arizona, United States
• Novartis Investigative Site — Scottsdale, Arizona, United States
• Novartis Investigative Site — Scottsdale, Arizona, United States
• Novartis Investigative Site — Tucson, Arizona, United States
• Novartis Investigative Site — Fort Smith, Arkansas, United States
• Novartis Investigative Site — Hot Springs, Arkansas, United States
• Novartis Investigative Site — Rogers, Arkansas, United States
• Novartis Investigative Site — Bakersfield, California, United States
• Novartis Investigative Site — Beverly Hills, California, United States
• Novartis Investigative Site — California City, California, United States
• Novartis Investigative Site — Encinitas, California, United States
• Novartis Investigative Site — Fresno, California, United States
• Novartis Investigative Site — Fullerton, California, United States
• Novartis Investigative Site — Irvine, California, United States
• Novartis Investigative Site — Los Angeles, California, United States
• Novartis Investigative Site — Oceanside, California, United States
• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.